JMJames R. Marshall

James R. Marshall

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


James R. Marshall has a total of 110 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Selenomethionine and methyl selenocysteine: multiple-dose pharmacokinetics in selenium-replete men

    by James R. Marshall, Raymond F. Burk, Rochelle Payne Ondracek, Kristina E. Hill, Marjorie Perloff, Warren Davis, Roberto Pili, Saby George, Raymond Bergan

    Selenomethionine and methyl selenocysteine: multiple-dose pharmacokinetics in selenium-replete men Selenomethionine and methyl selenocysteine: multiple-dose pharmacokinetics in selenium-replete men


  • Open Access

    Tobacco assessment in completed lung cancer treatment trials

    by Erica N. Peters, Graham W. Warren, Jeff A. Sloan, James R. Marshall

    An effort over 3 years to conduct a data pooling project regarding the association between smoking and lung cancer treatment outcomes has shown that, of 32 completed studies of lung cancer treatments in 1 National Cancer Institute Cooperative Group, only a minority have usable data concerning smoking‐related variables. Clinical trials research is needed to inform patients with cancer and their physicians about the impact of smoking, and how smoking cessation may affect the course of their disease.


  • Open Access

    Genome-Wide Association Study of Serum Selenium Concentrations

    by Jian Gong, Li Hsu, Tabitha Harrison, Irena B. King, Stefan Stürup, Xiaoling Song, David Duggan, Yan Liu, Carolyn Hutter, Stephen J. Chanock, et al.

    Selenium is an essential trace element and circulating selenium concentrations have been associated with a wide range of diseases. Candidate gene studies suggest that circulating selenium concentrations may be impacted by genetic variation; however, no study has comprehensively investigated this hypothesis. Therefore, we conducted a two-stage genome-wide association study to identify genetic variants associated with serum selenium concentrations in 1203 European descents from two cohorts: the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening and the Women’s Health Initiative (WHI). We tested association between 2,474,333 single nucleotide polymorphisms (SNPs) and serum selenium concentrations using linear regression models. In the first stage (PLCO) 41 SNPs clustered in 15 regions had p < 1 × 10−5. None of these 41 SNPs reached the significant threshold (p = 0.05/15 regions = 0.003) in the second stage (WHI). Three SNPs had p < 0.05 in the second stage (rs1395479 and rs1506807 in 4q34.3/AGA-NEIL3; and rs891684 in 17q24.3/SLC39A11) and had p between 2.62 × 10−7 and 4.04 × 10−7 in the combined analysis (PLCO + WHI). Additional studies are needed to replicate these findings. Identification of genetic variation that impacts selenium concentrations may contribute to a better understanding of which genes regulate circulating selenium concentrations.


  • Open Access

    Tobacco sales in pharmacies: a survey of attitudes, knowledge and beliefs of pharmacists employed in student experiential and other worksites in Western New York

    by Danielle M Smith, Andrew J Hyland, Cheryl Rivard, Edward M Bednarczyk, Peter M Brody, James R Marshall

    Pharmacies are venues in which patients seek out products and professional advice in order to improve overall health. However, many pharmacies in the United States continue to sell tobacco products, which are widely known to cause detrimental health effects. This conflict presents a challenge to pharmacists, who are becoming increasingly more involved in patient health promotion activities. This study sought to assess Western New York (WNY) area pharmacists’ opinions about the sale of tobacco products in pharmacies, and pharmacists’ opinions on their role in patient smoking cessation.


  • Diet and prostate cancer prevention

    by James R. Marshall

    To evaluate the present human-based evidence that diet is related to the risk and outcome of prostate cancer.


  • Open Access

    Phase III Trial of Selenium to Prevent Prostate Cancer in Men with High-grade Prostatic Intraepithelial Neoplasia: SWOG S9917

    by James R. Marshall, Catherine M. Tangen, Wael A. Sakr, David P. Wood, Donna L. Berry, Eric A. Klein, Scott M. Lippman, Howard L. Parnes, David S. Alberts, David F. Jarrard, et al.

    The threat of prostate cancer and the significant and often negative impact of its treatment underscore the importance of prevention. High-grade prostatic intraepithelial neoplasia (HGPIN) has been identified as a potential premalignant lesion marking an increased risk of prostate cancer and substantial evidence suggests that men with HGPIN are in need of prostate cancer prevention. In vitro, in vivo, epidemiologic, and clinical trial evidence that selenium supplementation protects against prostate cancer motivated the study we report here: a double-blind, randomized, placebo-controlled trial of selenium 200 (μg/d) as selenomethionine in men with HGPIN. The primary endpoint was progression of HGPIN to prostate cancer over a 3-year period. This National Cancer Institute Intergroup trial was coordinated by the Southwest Oncology Group (SWOG). Of 619 enrolled patients, 423 randomized men with HGPIN (212 selenium and 211 placebo) were eligible (by central pathology review) and included in the primary analysis. Three-year cancer rates were 36.6% (placebo) versus 35.6% (selenium; P = 0.73, adjusted). The majority of patients who developed cancer on trial (70.8%, selenium and 75.5%, placebo) had a Gleason score of 6 or less than 6; there were no differences in Gleason scores between the two arms. Subset analyses included the finding of a nonsignificantly reduced prostate cancer risk (relative risk = 0.82; 95% CI: 0.40–1.69) in selenium versus placebo patients in the lowest quartile of baseline plasma selenium level (Cancer Prev Res; 4(11); 1761–9. ©2011 AACR.


  • Open Access

    Methyl Selenocysteine: Single-Dose Pharmacokinetics in Men

    by James R. Marshall, Clement Ip, Karen Romano, Gerald Fetterly, Marwan Fakih, Borko Jovanovic, Marjorie Perloff, James Crowell, Warren Davis, Renee French-Christy, et al.

    The recently published report of the SELECT evaluation of selenium and vitamin E provided strong evidence that selenium 200 μg per day in the form of selenomethionine does not protect selenium-replete men against prostate or any other cancer. This seems to refute the result of the much smaller Nutritional Prevention of Cancer (NPC) trial of selenium. Because SELECT did not test the NPC agent, it is possible that the difference between the two trials stems partly from the use of different agents: selenomethionine in SELECT, and selenized yeast in the NPC trial. One of the organic selenium forms suspected of having strong chemopreventive effects, and which may have been present in the NPC agent, is methyl selenocysteine. This study characterizes the single-dose pharmacokinetics of methyl selenocysteine. Cancer Prev Res; 4(11); 1938–44. ©2011 AACR.


  • Open Access

    Characterization of the association between 8q24 and colon cancer: gene-environment exploration and meta-analysis

    by Carolyn M Hutter, Martha L Slattery, David J Duggan, Jill Muehling, Karen Curtin, Li Hsu, Shirley Aa Beresford, Aleksandar Rajkovic, Gloria E Sarto, James R Marshall, et al.

    Genome-wide association studies and subsequent replication studies have shown that single nucleotide polymorphisms (SNPs) in the chromosomal region 8q24 are associated with colorectal cancer susceptibility. We examined 11 SNP markers in the 8q24 region between 128.47 and 128.54 Mb, using a total of 1,987 colon cases and 2,339 controls who self-reported as white from two independent, well-characterized study populations. Analysis was performed separately within each study, and combined using random effects meta-analysis. Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (95% CIs) and to test for effect modification by known colon cancer risk factors. We also performed a meta-analysis combining our results with previous studies. We observed evidence of association for four SNPs in low to high linkage disequilibrium (r2 ranging from 0.18 to 0.93) localized in a 16.2 kb region defined by rs10505477 and rs1056368. The combined results for our two studies of colon cancer showed an OR of 1.10 (95% CI: 1.01-1.20, Ptrend = 0.023), and a meta-analysis of our results with previously reported studies of colon and colorectal cancer strongly support the association for this SNP (combined OR for rs6983267 = 1.21, 95% CI: 1.18-1.24, p = 5.5 × 10-44). We did not observe any notable evidence of effect modification by known colon cancer risk factors, and risk did not differ significantly by tumor site or stage. Our study confirms the association between polymorphisms on chromosome 8q24 and colon cancer risk and suggests that the susceptibility locus in region 8q24 is not strongly modified by various lifestyle, environmental, and demographic risk factors for colon cancer.


  • Nutrition and colon cancer prevention

    by James R Marshall

    In spite of improvements in care of colon cancer patients, prevention may enable potential patients to avoid cancer therapy. Although screening is direct and effective, dietary modification or low-risk chemopreventive agents might prevent colon cancer development. In this article, we review recent developments in colon cancer prevention, emphasizing nutrition. Epidemiologic findings continue to suggest that diet is related to colon cancer risk. These findings, although, are inconsistent enough to render dietary recommendations premature. An exciting recent discovery is that the combination of diflouromethylornithine and sulindac substantially decreases adenomatous polyp recurrence. Reliance upon clinical trials continues to grow as a means of testing prevention strategies. Prevention remains an important goal for reducing the burden of colon cancer. Screening has an important role, although it will probably not eliminate all colon cancer. Nutritional modification remains potentially valuable, although research has not yet identified the objects of nutritional intervention. NSAIDs hold promise as chemopreventive agents.